Nimbus Therapeutics Appoints Chief Medical Officer Annie C. Chen, M.D., MPH, to President of the Company’s Tyk2 Subsidiary
CAMBRIDGE, Mass. – December 17, 2019 – Nimbus Therapeutics, a biotechnology company coupling targets selected based on causal human biology with structure-based drug discovery and development, today announced the promotion of Chief Medical Officer, Annie C. Chen, M.D., MPH, to President of the company’s Tyk2 subsidiary, Nimbus Lakshmi, Inc. In this role, Dr. Chen will provide executive leadership for financial, business, and development activities associated with the company’s tyrosine kinase 2 (Tyk2) program, in addition to continuing her role as Chief Medical Officer for Nimbus Therapeutics.
“We’re at a very exciting juncture as Nimbus gears up to once again become a clinical-stage company, and there is no better person to helm that effort than Annie,” said Jeb Keiper, M.S., MBA, Chief Executive Officer of Nimbus. “Annie’s extensive background in immunology, her experience leading clinical strategy to bring multiple therapies forward to regulatory approval, and her passionate dedication as a clinician to the well-being of her patients will be of enormous value to our Tyk2 program as it advances into the clinic.”
“Tyk2 is a genetically validated target for the treatment of many autoimmune and inflammatory disorders, and through Nimbus’ structure-based drug discovery efforts, we have developed promising allosteric modulators that effectively inhibit this target,” said Dr. Chen. “I’m honored to lead these multidisciplinary efforts for Nimbus as we initiate clinical studies and chart the program’s future path.”
Dr. Chen, who received her medical training as an adult rheumatologist, has served as Chief Medical Officer of Nimbus since 2015. She provided oversight for the company’s acetyl CoA carboxylase clinical program for NASH and supported business development and financing efforts, before its acquisition by Gilead. Prior to joining Nimbus, Dr. Chen was Executive Director of Clinical Research, Section Head of Vaccines at Merck and Co., where she oversaw clinical research activities for a broad portfolio of vaccines, from discovery through registration and life cycle management. Dr. Chen also held the role of Section Head of Immunology, where she oversaw clinical research for small molecule and protein therapeutics. Prior to Merck, Dr. Chen held roles of increasing responsibility at Genentech, and began her career at Celera Genomics.
About Nimbus Therapeutics
Nimbus Therapeutics designs breakthrough medicines. Utilizing its powerful structure-based drug discovery engine, Nimbus designs potent and selective small molecule compounds targeting proteins that are known to be fundamental drivers of pathology in highly prevalent human diseases and that have proven difficult for other drug makers to tackle. The company’s LLC/subsidiary architecture enables diverse and synergistic partnerships to deliver breakthrough medicines. Nimbus is headquartered in Cambridge, Mass. For more information, please visit www.nimbustx.com.
Lisa Raffensperger, (617) 903-8783
Ten Bridge Communications